This study investigates pancreatic cancer. It explores the use of DNA nanomachines for detecting microRNA in the blood.
The study evaluates the role of these DNA nanomachines and their potential applications in diagnosing pancreatic cancer by developing a fluorescence sensing platform.
- Who can participate: Adults 20 years and older with pancreatic ductal adenocarcinoma proven by pathology can participate. Participants should not have received any anti-cancer therapies and must not have other active malignancies.
- Study details: Participants will have their blood tested using an investigational method involving DNA nanomachines to detect microRNA. This method employs a fluorescence sensing platform for dual signal amplification. An inactive substance that looks like the investigational medicine/vaccine but does not contain any medicine is not involved.